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ABSTRACT The aim of this study was to describe the impact of chronic obstructive pulmonary disease
(COPD) on health status in the Burden of Obstructive Lung Disease (BOLD) populations.
We conducted a cross-sectional, general population-based survey in 11 985 subjects from 17 countries.
We measured spirometric lung function and assessed health status using the Short Form 12 questionnaire.
The physical and mental health component scores were calculated.
Subjects with COPD (post-bronchodilator forced expiratory volume in 1 s/forced vital capacity ,0.70,
n52269) had lower physical component scores (44¡10 versus 48¡10 units, p,0.0001) and mental health
component scores (51¡10 versus 52¡10 units, p50.005) than subjects without COPD. The effect of
reported heart disease, hypertension and diabetes on physical health component scores (-3 to -4 units)
was considerably less than the effect of COPD Global Initiative for Chronic Obstructive Lung Disease grade
3 (-8 units) or 4 (-11 units). Dyspnoea was the most important determinant of a low physical and mental
health component scores. In addition, lower forced expiratory volume in 1 s, chronic cough, chronic
phlegm and the presence of comorbidities were all associated with a lower physical health component score.
COPD is associated with poorer health status but the effect is stronger on the physical than the mental
aspects of health status. Severe COPD has a greater negative impact on health status than self-reported
cardiovascular disease and diabetes.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is not fully
reversible and accelerated decline of lung function. The disease is an important and growing cause of
morbidity and mortality worldwide. COPD is expected to be the third leading cause of morbidity and the
sixth leading cause of mortality in 2020 [1]. Patients with COPD experience respiratory symptoms and
physical incapacity and often have several comorbid conditions. Consequently, they often have impaired
health status or health-related quality of life, which in itself is an independent predictor of hospitalisations [2]
and mortality [2, 3]. Low lung function [4], female sex [5], frequent exacerbations [4, 6], comorbidities [4]
and a low level of physical activity [7] have been identified as factors that negatively influence health status in
COPD, whereas physical exercise training [8, 9] and pharmacological interventions can have a positive effect
on health status [10, 11]. However, the nature of the impact and the factors that influence health status are not
well understood.
The major purpose of the Burden of Obstructive Lung Disease (BOLD) study is to estimate the social and
economic burden of COPD around the world [12]. The study includes standardised measurement of
spirometric lung function and a structured interview that incorporates the Short Form 12 (SF-12)
questionnaire [13]. Previous BOLD analyses have concentrated on prevalence [12], risk factors [14] and
economic aspects [15] of COPD. However, for the individual patient the major impact of the disease is
manifest as deterioration in health status. The aims of the analyses in this paper are to describe the impact of
COPD on health status in adults aged o40 years and to identify determinants of low health status in people
with COPD.
Population and methods
The design and rationale for the BOLD Initiative and preliminary data on prevalence have been published
elsewhere [13]. Sampling plans designed to randomly recruit a representative sample of the population were
used for the recruitment of participants at all study sites. The present analysis included data from 18 sites in
17 countries for subjects in whom valid spirometry and health status data were obtained. The sites were:
Adana (Turkey), Salzburg (Austria), Cape Town (South Africa), Reykjavik (Iceland), Hannover (Germany),
Krakow (Poland), Bergen (Norway), Vancouver (Canada), Lexington (USA), Manila (Philippines), Sydney
(Australia), London (United Kingdom), Uppsala (Sweden), Mumbai (India), Lisbon (Portugal), Maastricht
(the Netherlands), Nampicuan/Talugtug (Philippines) and Tartu (Estonia).
Each participating site aimed to recruit a population-based sample of at least 600 adults (300 males and 300
females) who were not institutionalised, were aged o40 years, and were living in a well-defined
administrative area in which the total population exceeded 150 000. Target recruitment numbers, as well as
the sampling plans, were approved in advance by the Operations Center (Portland, OR, USA).
Questionnaires were used to obtain information about respiratory symptoms, health status, comorbidities
and risk factors for COPD. Pre- and post-bronchodilator spirometry testing was performed. Every site
obtained approval from its local ethics committee and written informed consent from each participant.
The study population consisted of 14 450 subjects of whom 13 495 had recorded health status data and, of
these, 11 985 subjects performed a technically satisfactory spirometry whereas 1510 did not have a
technically satisfactory spirometry recording according to the pre-defined criteria of the BOLD protocol [13].
Spirometry and body mass index
Lung function data were obtained at all BOLD sites using the ndd EasyOne Spirometer (ndd Medical
Technologies, Andover, MA, USA). Lung function was measured before and 15 min after administration of
200 mg of salbutamol. All spirograms were reviewed by the BOLD Pulmonary Function Reading Center and
assigned a quality score based on acceptability and reproducibility criteria of the American Thoracic Society
and European Respiratory Society guidelines [16]. Prediction equations derived from the third US National
Health and Nutrition Examination Survey were used to compute predicted forced expiratory volume in 1 s
(FEV1) [17]. Weight and height were measured at the clinic visit by trained technicians and body mass
index (BMI) was calculated (weight (kg)/(length (m))2). The participants were categorised into four groups
based on BMI: ,20, 20–25, .25–30 and .30 kg?m-2.
Definition and classification of COPD
COPD was defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
as post-bronchodilator FEV1/forced vital capacity (FVC) ,0.70 [18]. We also performed sensitivity
analyses, defining COPD as post-bronchodilator FEV1/FVC predicted below the lower limit of normal
(LLN) [17]. Subjects with COPD and FEV1 o80% predicted were classified as GOLD grade 1; those with
COPD and FEV1 ,80% but FEV1 o50% predicted were classified as GOLD grade 2; those with COPD and
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FEV1 ,50% but FEV1 o30% predicted were classified as GOLD grade 3 and those with COPD and FEV1
,30% predicted were classified as GOLD grade 4 [18].
Questionnaire data
Questionnaire data were obtained by face-to-face interviews administered by trained and certified staff in
the participant’s native language. Standard methods were used for forward and backward translation and
reconciliation. All participants completed a core questionnaire, which was based on standardised
instruments [13].
Health status
Health status was assessed by the SF-12 questionnaire (version 2), which is a generic instrument for
assessing health status. The instrument was developed from the short form 36 (SF-36) questionnaire
developed to catch the mental and physical score of the SF-36 using only 12 questions compared with the 36
questions in the SF-36 instrument. The physical (PCS) and mental health (MCS) component scores were
calculated [19], with higher values indicating better health status.
Educational level
Educational level was calculated in years based on the question: ‘‘How many years of schooling have you
completed?’’
Smoking history
The participants were categorised as never-, ex- and current smokers. Smoking was defined as .20 packs of
cigarettes in a lifetime or .1 cigarette each day for a year.
Comorbidities
Heart disease was defined as answering ‘‘yes’’ to the question: ‘‘Has a doctor or other healthcare provider ever
told you that you had heart disease?’’. Hypertension, diabetes and stroke were defined in a similar manner.
Dyspnoea was graded using a modification of the Medical Research Council dyspnoea scale [20]. Stage 0
was defined as answering ‘‘no’’ to the question: ‘‘Are you troubled by shortness of breath when hurrying on
the level or walking up a slight hill?’’ and stage IV as a positive answer to the question: ‘‘Are you too short of
breath to leave the house or short of breath on dressing or undressing?’’
Symptoms
The following symptoms were included in the analyses: wheeze: ‘‘wheezing or whistling in the chest at any
time in the last 12 months’’; chronic cough: ‘‘cough on most days for as much 3 months each year’’; and
chronic phlegm: ‘‘bringing up phlegm from the chest, having phlegm in the chest that is difficult to bring up
on most days for as much as 3 months each year’’.
Medication
The level of medication for breathing problems was categorised into four groups based on the participants
answer to the questions. ‘‘In the past 12 months, have you taken any medications for your breathing?’’ If the
participants answered yes, the name and formulation of the medication was asked for. In the present
analyses, medication level 0 was no bronchodilators or inhaled corticosteroids (ICSs); level 1 was short-
acting b2-agonists or ipratropium but no long-acting b2-agonists (LABAs), tiotropium, theophylline
or ICSs; level 2 was LABAs, tiotropium or theophylline but no ICSs; and level 3 was ICSs with or
without bronchodilators.
COPD exacerbation
COPD exacerbation was defined as a reported medical visit for an episode of breathing problems that
interfered with usual daily activities in a subject with COPD.
Statistical analysis
All analyses were performed in STATA software, version intercooled STATA 11 (Stata Corporation, College
Station, TX, USA). Differences between subjects with and without COPD were tested by the t-test and Chi-
squared test. The association between FEV1 and health status in subjects with COPD was evaluated by linear
regression. Multiple linear regression was used in the multiple variable analyses with PCS and MCS,
respectively, as dependent variables in the whole population and in the subpopulation with COPD. In these
analyses, adjustments were made for age, sex, BMI, smoking history and educational level. Regression
models were fitted separately for each site and results for the association between health status and COPD
were pooled across sites using random effects meta-analysis in order to detect heterogeneity between the
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centres [21]. Heterogeneity was quantified using the I2 statistic [22]. A p-value of ,0.05 was considered
statistically significant.
Results
The characteristics of the 11 985 subjects who had both health status data and a technically satisfactory
spirometry, grouped by COPD status, are presented in table 1. Participants with COPD (n52269) were
significantly older, more often male, had a lower BMI, lower educational level and had a higher prevalence
of heart disease, hypertension and stroke than those without COPD (table 1).
Sample population
Participants with COPD had lower PCS (44¡10 versus 48¡10 units, p,0.0001) and MCS (51¡10 versus
52¡10 units, p50.005) than participants without COPD. The severity of COPD was inversely correlated
with both these scales (figure 1).
In the multivariate analyses, both PCS and MCS were inversely related to COPD severity (table 2). The
strength of the relationship between health status and COPD, as well as other diseases, is presented in
figure 2 and table 2. The presence of heart disease, hypertension and diabetes was associated with lower PCS
and MCS. Stroke was only significantly related to lower PCS. The effect of these non-COPD diseases on PCS
was of approximately the same magnitude as the effect of having COPD GOLD grade 2, but considerably
less than the effect of GOLD grade 3 and 4 (fig. 2). The estimated effect of having COPD of any severity was
of the same level of magnitude as having self-reported heat disease and diabetes.
The combined effect of COPD severity level and the presence of comorbidities on PCS are presented in
figure 3. Having COPD GOLD grade 1 was only associated with lower PCS if the subject also had heart
disease, hypertension, diabetes or stroke. Subjects with COPD grade 3 and 4 and any of these comorbidities
had the lowest PCS.
Female sex, current smoking and having a BMI ,20 kg?m-2 were also associated with lower PCS and MCS
(table 2). Ex-smoking status, a lower educational level and having a BMI .30 kg?m-2 were all associated
with a lower PCS. Finally, older age was associated with a lower PCS but a higher MCS.
The random effects meta-analysis estimate of the effect of having COPD grade 2 and higher was a PCS that
was mean (95% confidence interval) 4.3 (3.6–4.9) units lower (fig. 4). There was no significant between-
centre heterogeneity in the association between PCS and GOLD grade 2+ (fig. 4). Having COPD was
associated with a 1.8 (0.8–2.8) units lower MCS (fig. 5). There was significant and large between-centre
heterogeneity in the association between MCS and GOLD grade 2+ (fig. 5). This heterogeneity was largely
explained by a stronger association between COPD grade 2+ and MCS in Mumbai, India. With Mumbai
TABLE 1 Characteristics of the participants according to severity of airflow limitation grouped by Global Initiative for Chronic
Obstructive Lung Disease grade
No COPD Grade 1 Grade 2 Grade 3 Grade 4 p-value#
Subjects n 9716 1027 945 257 40
Females 54.0 41.0 44.2 42.4 47.5 ,0.0001
Age years 55.2¡10.8 64.9¡12.2 64.0¡11.2 63.4¡11.7 60.1¡9.9 ,0.0001
Years of education 11¡5 11¡4 10¡4 9¡4 8¡4 ,0.0001
Smoking history ,0.0001
Never-smoker 49.3 33.8 27.7 19.5 22.5
Ex-smoker 29.5 39.8 37.4 42.4 50.0
Current smoker 21.2 26.4 34.9 38.1 27.5
Body mass index kg?m-2 ,0.0001
,20 5.9 4.8 14.2 28.0 47.5
20–25 31.8 35.3 29.6 27.6 37.5
.25–30 38.0 42.3 32.9 25.2 12.5
.30 24.4 17.6 23.3 19.3 2.5
Comorbidities
Heart disease 12.6 19.6 22.9 18.3 5.0 ,0.0001
Hypertension 30.2 36.4 39.4 31.9 24.4 ,0.0001
Diabetes 7.4 7.2 9.0 11.7 7.5 0.09
Stroke 2.6 3.6 5.7 3.9 5.0 ,0.0001
Data are presented as % or mean¡SD, unless otherwise stated. COPD: chronic obstructive pulmonary disease. #: no COPD versus COPD.
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removed from the meta-analysis, the between centre heterogeneity was no longer statistically significant
(I2518.2, pheterogeneity50.24).
Redefining COPD using FEV1/FVC ratio ,LLN rather than the FEV1/FVC ratio ,0.70 as the criterion for
airflow limitation reduced the number of subjects with COPD from 2269 (18.9%) to 1520 (12.7%), but had
no effect on the association between COPD grades and health status (table 3).
Participants who did not perform a technically satisfactory spirometry had lower PCS (45¡11 versus
48¡10 units, p,0.0001) than those that performed a satisfactory spirometry, while there was no difference
in MCS (51 units in both groups).
COPD population
Among subjects with COPD grade 1 or higher, lower FEV1 was independently related to lower PCS but not
significantly associated with MCS, after adjusting for the other covariates (table 4). Dyspnoea was the most
important determinant of a low PCS and MCS (ptrend,0.0001). PCS and MCS were also negatively related
to female sex and wheeze. Higher age was associated with lower PCS and higher MCS. In addition a low
PCS was related to chronic cough, chronic phlegm, heart disease, diabetes and stroke and a
BMI.30 kg?m-2, while a low MCS was related to a BMI,20 kg?m-2 and current smoking (adjusted effect
estimate (95% CI) -1.49 (-2.71– -0.28)).
Among subjects with COPD, 18.2% were using bronchodilators or ICSs. Adjusting for level of medication
use did not change the previously reported associations. Having had at least one exacerbation of COPD
within the last 12 months, which was reported by 7.3% of subjects with COPD, was associated with lower
PCS (adjusted estimate (95% CI) -2.58 (-4.53– -0.63)), whereas no significant association was found
between MCS and exacerbations. Including exacerbations in the model did not change the associations
reported above.
Among subjects with COPD, the relationship between each of these risk factors and health status was not
modified by sex.
Discussion
The main finding in this article is that COPD is an important determinant of health status, but that the
effect is stronger on the physical than the mental aspects of health status. COPD severity and current
smoking were both independently related to poorer health status. Among people with COPD, physical
health status was independently related to lower lung function, the level of dyspnoea and cardiovascular
comorbidities, while mental health status was mainly related to the level of dyspnoea.
In our analyses, only subjects with COPD GOLD grade 2 and higher had worse health status that those
without COPD. Health status did not differ between subjects with COPD grade 1 and subjects without
COPD. As in several other studies, the impact of COPD was larger on the physical than the mental aspects
of health status [5, 23, 25]. In accordance with previous studies the negative impact on health status
increased with increasing COPD severity [25–27]. The actual SF-12 scores in BOLD participants were
similar to those from other population-based studies [5], but the scores were considerably higher, indicating
better health status, than in a large European study of patients in primary healthcare setting [26].
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This investigation is unique in the sense that it includes many countries and cultures. Despite this, we found
no evidence of geographical differences in the strength of association between physical health status and
COPD. As an example, the association between PCS and having COPD stage II or higher was of equal
magnitude in high income countries, such as Norway and Canada, to India The weak association between
mental health status and COPD was also geographically consistent with the exception of a very strong
negative association between COPD grade 2 and higher and MCS in India.
In the present study we used the SF-12 questionnaire. A large number of instruments have been used when
assessing health status or health-related quality of life in COPD. These include both disease-specific
instruments, such as St George’s Respiratory Questionnaire [28], and generic instruments, such as SF-36
[29]. Recently, shorter questionnaires have been used in order to facilitate measurement of health status in
TABLE 2 Associations between Short Form (SF)-12 physical component score (PCS) and mental health component score (MCS)
with chronic obstructive pulmonary disease (COPD) defined as having a post-bronchodilator forced expiratory volume in 1s
(FEV1)/forced vital capacity (FVC) ,0.70
PCS SF-12 MCS SF-12
No COPD Reference Reference
COPD (FEV1/FVC ,0.70)
Grade 1 -0.19 (-0.78–0.39) 0.07 (-0.55–0.69
Grade 2 -3.0 (-3.6– -2.4) -1.4 (-2.1– -0.77)
Grade 3 -7.8 (-8.9– -6.7) -3.1 (-4.3– -2.0)
Grade 4 -11 (-14– -8.9) -5.2 (-8.1– -2.3)
Age per 10 years -1.2 (-1.6– -0.8) 0.84 (0.67–1.0)
Females compared with males -2.0 (-2.3– -1.6) -2.2 (-2.5– -1.8)
Years of education per year 0.23 (0.19–0.28) 0.05 (0.00–0.10)
Smoking history
Never Reference Reference
Ex -0.39 (-0.77– -0.01) -0.38 (-0.79–0.03)
Current -1.8 (-2.2– -1.3) -1.8 (-2.3– -1.3)
Body mass index kg?m-2
,20 -1.0 (-1.7– -0.37) -1.0 (-1.8– -0.32)
20–25 Reference Reference
.25–30 -0.54 (-0.92– -0.15) 0.05 (-0.36–0.46)
.30 -2.9 (-3.3– -2.4) 0.05 (-0.43–0.54)
Comorbidities
Heart disease -3.1 (-3.6– -2.6) -0.78 (-1.3– -0.26)
Hypertension -1.2 (-1.6– -0.85) -0.80 (-1.2– -0.41)
Diabetes -2.7 (-3.3– -2.1) -0.76 (-1.4– -0.10)
Stroke -4.5 (-5.4– -3.5) -0.23 (-1.2–0.77)
Data are adjusted for the variables in the table and centre are presented as adjusted estimates (95% confidence interval).
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clinical or epidemiological settings. Examples of shorter health status questionnaires are disease-specific
instruments, such as Clinical COPD Questionnaire [30, 31] and the COPD Assessment Test (CAT) [4], and
generic instruments, such as EuroQol 5 dimension and SF-12 [32].
The advantage of a generic questionnaire is that it enabled us to compare the effect of different diseases on
health status. In this study, the negative influence of self-reported heart disease, diabetes and stroke was of
similar magnitude to the effect of COPD grade 2, but considerably less than the effect of COPD grades 3 and
4. It is well known that many patients with COPD have extrapulmonary comorbidities that generate
significant healthcare costs [33, 34], have a negative effect on rehabilitation outcome [35] and increase the
risk of hospitalisations and mortality in COPD patients [36]. Comorbidity may also influence health status
in COPD [24]. In the present study, self-reported heart disease had a negative influence on PCS but not
MCS. This finding is in accordance with other studies [26, 37]. We also found that diabetes was
independently related to lower health status in our participants with COPD. This has been observed in some
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FIGURE 4 Effect estimates and 95% confidence intervals for the association between the Short Form-12 physical
component score and chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic Obstructive Lung
Disease grade 2 and higher compared with participants without COPD (adjusted within centre for age, sex, educational
level, smoking history, comorbidities and body mass index) with a combined effect estimate (diamond indicates 95%
confidence interval) from the model with centre as the random effect. The size of each square is proportional to the sample size.
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[38], but not all, previous studies [39]. There was an additive effect of COPD severity and comorbidities on
impairment of health status in subjects with COPD.
Dyspnoea was independently negatively related to both PCS and MCS in both the present study and in a
previous study [40]. Apart from dyspnoea and FEV1, PCS was also related to chronic cough, chronic
phlegm and wheeze. In recent years, increased attention has been paid to symptoms associated with COPD.
This might be due to the fact that dyspnoea and other respiratory symptoms indicate a worse prognosis in
COPD, independent of the level of airflow limitation [41, 42]. Another reason might be that in subjects with
COPD, improvement in symptoms may be easier to achieve than improvement in lung function.
In the present study, females with COPD had lower health status than males with COPD. This is a
replication of findings from several other studies [5, 40, 43]. A low BMI was related to lower MCS and a
higher BMI to lower PCS in our investigation. Several other studies have found that both being underweight
and being obese are related to decreased health status [39, 44, 45]. In accordance with other studies, higher
educational level was associated with better health status [46, 47].
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FIGURE 5 Effect estimates and 95% confidence intervals for the association between the SF-12 mental component score
and chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic Obstructive Lung Disease grade 2 and
higher compared with participants without COPD (adjusted within centre for age, sex, educational level, smoking history,
comorbidities and body mass index) with a combined effect estimate (diamond indicates 95% confidence interval) from
the model with centre as the random effect. The size of each square is proportional to the sample size.
TABLE 3 Associations between Short Form (SF)-12 physical component score (PCS) and
mental health component score (MCS) with chronic obstructive pulmonary disease (COPD)
defined as having a post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital
capacity (FVC) predicted below the lower limit of normal (LLN)
PCS SF-12 MCS SF-12
No COPD Reference Reference
COPD (FEV1/FVC ,LLN)
Grade 1 -0.26 (-1.05–0.53) -0.28 (-1.13–0.56)
Grade 2 -3.2 (-3.9– -2.5) -1.2 (-1.9– -0.44)
Grade 3 -7.9 (-9.0– -6.8) -2.9 (-4.1– -1.7)
Grade 4 -12 (-14– -8.8) -5.1 (-8.0– -2.2)
Data are presented as adjusted estimates (95% confidence interval). Estimates are adjusted for age, sex,
educational level, smoking history, body mass index, cardiovascular diseases, diabetes and centre.
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The BOLD study is one of several large epidemiological studies that have examined health status in people
with COPD. The Epidemiologic Study of COPD in Spain (EPI-SCAN) has highlighted the importance of
impaired health status in people with undiagnosed COPD [48]. The Latin American Project for the
Investigation of Obstructive Lung Disease (PLATINO) has focused on sex differences and has shown that
health status was lower in females than males [5]. The Canadian Obstructive Lung Disease prevalence study
has been used to validate the CAT. Components of CAT can be of value for identifying subjects with
previously undiagnosed COPD [49].
Strengths of this study include the large sample size and the use of a standardised method of data collection,
together with a high level of quality control that increases the internal validity of the analyses [12, 13]. Also,
BOLD includes subjects from a large number of countries, which increases the external validity of our
findings. The use of questionnaires in different languages may introduce problems. However, in BOLD, the
translations of the original questionnaires have been validated. Another possible limitation is that we did
not collect data on depression, which has been shown to be related to health status in patients with COPD
[50]. As the protocol did not include the CAT, we were not able to classify the subjects according to the
newly developed GOLD groups A–D [18]. Finally, lack of a disease-specific health status questionnaire and
the fact that the information on comorbidities was self-reported should be taken into account when
interpreting our findings.
We confirm that COPD is related to worse health status and that the effect on the physical aspects of health
status is stronger than the effect on the mental aspects. In severe COPD, the degree of impairment in health
status is greater than the effect seen in people with self-reported cardiovascular diseases and diabetes. In
subjects with COPD, health status is related to low lung function, dyspnoea, symptoms and comorbidities.
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